Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 2/6 |
Past Performance | 2/6 |
Financial Health | 6/6 |
Dividends | 4/6 |
Zhejiang Xianju Pharmaceutical Co.,Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥11.09 |
52 Week High | CN¥13.40 |
52 Week Low | CN¥8.44 |
Beta | -0.34 |
11 Month Change | -2.80% |
3 Month Change | -5.62% |
1 Year Change | -10.28% |
33 Year Change | -8.27% |
5 Year Change | 76.59% |
Change since IPO | 24.58% |
Recent News & Updates
Shareholder Returns
002332 | CN Pharmaceuticals | CN Market | |
---|---|---|---|
7D | -1.7% | -5.9% | -3.0% |
1Y | -10.3% | -17.9% | -21.8% |
Return vs Industry: 002332 exceeded the CN Pharmaceuticals industry which returned -17.9% over the past year.
Return vs Market: 002332 exceeded the CN Market which returned -21.8% over the past year.
Price Volatility
002332 volatility | |
---|---|
002332 Average Weekly Movement | 5.4% |
Pharmaceuticals Industry Average Movement | 5.0% |
Market Average Movement | 5.7% |
10% most volatile stocks in CN Market | 9.0% |
10% least volatile stocks in CN Market | 3.8% |
Stable Share Price: 002332 has not had significant price volatility in the past 3 months.
Volatility Over Time: 002332's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1972 | 3,281 | Weihua Jin | www.xjpharma.com |
Zhejiang Xianju Pharmaceutical Co.,Ltd. manufactures and sells steroids and hormones worldwide. The company offers gynecological, anesthesia, respiratory, dermatology, generic drug, and other products; and active pharmaceutical ingredients (API), such as corticosteroids, sex hormone, progesterone, non-hormone series, newchem API, and intermediates products.
Zhejiang Xianju Pharmaceutical Co.,Ltd. Fundamentals Summary
002332 fundamental statistics | |
---|---|
Market cap | CN¥10.97b |
Earnings (TTM) | CN¥581.09m |
Revenue (TTM) | CN¥4.20b |
18.9x
P/E Ratio2.6x
P/S RatioIs 002332 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
002332 income statement (TTM) | |
---|---|
Revenue | CN¥4.20b |
Cost of Revenue | CN¥1.98b |
Gross Profit | CN¥2.22b |
Other Expenses | CN¥1.64b |
Earnings | CN¥581.09m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 27, 2024
Earnings per share (EPS) | 0.59 |
Gross Margin | 52.87% |
Net Profit Margin | 13.82% |
Debt/Equity Ratio | 3.3% |
How did 002332 perform over the long term?
See historical performance and comparison